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Abstract. A patient with renal cell cancer developed acute 
renal failure due to biopsy-proven acute tubulo-interstitial 
nephritis (AIN) in the 6th week of continuous infusion of
9 x  106 IU n r 2 day-1 recombinant interleukin-2 (rIL-2). 
We investigated whether the AIN was the result of a cellu­
lar cytotoxic reaction induced by the rIL-2 treatment. The 
cytolytic activity of cryopreserved peripheral blood lym­
phocytes (PBL), isolated before and at the end of the rIL-2 
treatment (at the time of AIN), was studied after 5 days of 
culture with or without rIL-2 or anti-CD28 and immobi­
lized anti-CD3 antibodies. The PBL isolated before and at 
the end of the rIL-2 treatment showed cytolytic activity 
towards a number of allogeneic targets. However, only the 
PBL isolated at the end of the rIL-2 treatment showed, 
when stimulated with rIL-2 in vitro, significant cytolytic 
activity against an autologous renal cell line cultured from 
the AIN biopsy specimen and against an allogeneic renal 
cell cancer cell line. These PBL displayed no enhanced 
killing capacity towards autologous PBL and the melano­
ma cell line M14. These observations suggest that the AIN 
may be the result of a cytotoxic lymphocyte-mediated reac­
tion induced by the rIL-2 treatment.
Key words: Acute interstitial nephritis -  Renal cell can­
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Introduction
The immunological nature of acute (tubulo)interstitial ne­
phritis (AIN) is well established [20]. Experimental data 
indicate that the loss of immunological tolerance towards 
endogenous tubulo-interstitial antigens is the hallmark of
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the pathogenesis of AIN. Helper (CD4+) T cells, respond­
ing to these antigens, may activate B and effector (CD8+) 
T lymphocytes. Antigen-specific delayed hypersensitivity, 
cell-mediated cytotoxicity, complement-mediated cytotox­
icity or antibody-dependent cellular cytotoxicity (ADCC) 
may lead to tubulo-interstitial damage. The tubulo-intersti­
tial inflammatory infiltrate mainly consists of macrophages 
and helper and cytotoxic (CD8+) T lymphocytes and may 
be associated with the deposition of immune complexes or 
specific antibodies along the tubular basement membrane, 
depending on the underlying pathogenic mechanism. In 
man, antigen-specific cell-mediated injury is most com­
mon. The disorder is mostly triggered by an infection or the 
use of drugs [7,20].
Immune-mediated renal injury is well documented in 
patients with cancer including renal cell carcinoma and in 
patients treated with various modes of immunotherapy 
[11,18]. Mostly the renal involvement consists of glomer­
ular damage due to immune-complex deposition. The na­
ture of the antigen is not well established [3, 14]. Tubulo- 
interstitial abnormalities are uncommon [3], and only a few 
cases of clinically apparent interstitial nephritis in these 
patients have been reported [1,10,28].
Renal failure occurring during treatment with recombi­
nant interleukin-2 (rIL-2) is mostly attributed to hypoper­
fusion of the kidneys, and is usually reversible after discon­
tinuation of rIL-2 administration [4, 26]. However, the 
presence of intrinsic renal lesions is suggested by recent 
. functional studies [25], the occasional occurrence of urine 
sediment abnormalities [4], proteinuria [2] and biochemi­
cal evidence of proximal tubular injury [26]. The patholog­
ical features, consisting of interstitial lymphoid infiltrates 
with tubular dilatation and atrophy, are poorly correlated 
with the clinically apparent renal dysfunction [16]. Re­
cently, a case of histologically documented AIN has been 
. described in a melanoma patient following treatment with 
rIL-2 and lymphokine-activated killer cells [10]. We ob­
served a case of acute renal failure due to biopsy-proven 
acute tubulo-interstitial nephritis (AIN) during treatment 
with rIL-2 alone for advanced renal cell cancer [8]. In the 
present study we show that the cytotoxic capacity of in
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vitro activated peripheral blood lymphocytes (PBL) isolat­
ed at the end of the rEL-2 treatment (at the time of the AIN) 
was enhanced towards an autologous renal cell line cul­
tured from the AIN biopsy specimen and an allogeneic 
renal cancer cell line, but not towards autologous PBL or 
the allogeneic melanoma cell line M14.
Case report
A 58-year-old Caucasian man with pleural metastases from renal cell 
carcinoma underwent left-sided nephrectomy prior to treatment with 
rIL-2. The nephrectomy specimen showed renal adenocarcinoma with 
extensive lymphocytic infiltration. No abnormalities were seen in the 
contiguous renal parenchyma. Continuous infusion over 24 h of
9 x  106IU/m2 rIL-2 (Euro-Cetus, Amsterdam, the Netherlands) was 
started through a central venous access for a period of 6 weeks according 
to a phase I protocol on an out-patient basis [27]. At the end of the 
6th week of treatment, oliguria with acute renal failure developed 
without signs of vascular leakage syndrome. Treatment with rIL-2 was 
discontinued. Persistent renal failure prompted haemodialysis. A surgical 
biopsy specimen of the right kidney taken 2 weeks after discontinuation 
of the rIL-2 treatment showed normal glomeruli with a dense interstitial 
infiltrate consisting of lymphocytes, plasma cells and eosinophilic and 
neutrophilic granulocytes. This infiltrate extended into the tubules. Im­
munofluorescence examination with antibodies against IgG, IgM, IgA, 
total complement, and complement factors B1A and Clq showed no 
glomerular or specific tubular deposition (F. J. W. ten Kate, Department 
of Pathology, Erasmus University, Rotterdam, the Netherlands). 
Methylprednisolone pulse therapy resulted in normalization of the renal 
function. Four months later the patient died from rapid tumour progres­
sion. A request for autopsy was not granted.
Materials and methods
Preparation o f effector cells: Peripheral blood of the patient was col­
lected in preservative-free heparin and mononuclear cells were isolated 
by centrifugation on FicolL/Hypaque density gradients and were stored in 
liquid nitrogen until testing. Samples were taken before and at the end of 
the 6 weeks of rIL-2 treatment.
After thawing, the isolated peripheral blood lymphocytes (PBL) were 
cultured for 5 days in medium consisting of Iscove’s modified Dul- 
becco’s medium (IMDM) with 5% pooled human serum, 100 U/xnl peni­
cillin and 100 |Xg/ml kanamycin and in medium with 600 IU/ml r3L-2. In 
order to induce T cell proliferation and activation the PBL were cultured 
in medium with 600 U/ml rIL-2 plus anti-CD28 (1 |ig/ml) and‘immobi­
lized anti-CD3 (0.5 jXgAvell) antibodies for 5 days [21].
The biopsy specimen of the interstitial nephritis (0.1 cm3) was 
minced, homogenized and centrifuged over Ficoll/Hypaque. From the 
homogenate 0.9 x 106 lymphocytes and 0.1 x  106 non-lymphocytic 
cells were isolated. Unfortunately, the cryopreserved kidney-infiltrating 
lymphocytes were not viable after thawing so they could not be used as 
effector cells.
Because the nephrectomy specimen containing the renal cell cancer 
consisted merely of non-viable cells and was infected, neither tumour- 
infiltrating lymphocytes nor a renal tumour cell line could be cultured.
Preparation o f target cells. A slowly growing cell line was cultured from 
the 0.1 x  106 non-lymphocytic cells isolated from the renal biopsy 
specimens at the time of AIN. These cells were considered to be non- 
malignant human epithelial cells of renal origin (autologous renal cell 
line, ARCL). They stained positively with the monoclonal antibodies 
G250 (IgGl) and RC38 (IgGl) and with monoclonal antibodies directed 
to HLA-class I, p2-microglobulin and a-keratin [22, 23]. The other tar­
gets consisted of the renal cancer cell line BA, which was generated from 
a renal cell carcinoma of another patient, the natural-Jailer-cell(NK)-re­
sistant melanoma cell line M l4, the NK-sensitive erythroleukemia cell 
line K562 and autologous PBL sampled before rIL-2 treatment.
The cell lines ARCL, BA, M14 and K562 were cultured in medium 
consisting of IMDM with 10% fetal calf serum, 100 U/ml penicillin and
Table 1. Distribution of the surface antigens of the peripheral blood 
effector lymphocytes before and at the end of 6 weeks recombinant-inter- 
leukin-2 (rIL-2) treatment cultured in medium alone, in medium with 
600 IU/ml rIL-2, or in medium with 600 IU/ml rIL-2 with anti-CD28 
( 1 jig/ml) and immobilized anti-CD3 (0.5 |ig/well) antibodies
Antigen Percentage of cells positive
Before rIL-2 6 weeks after rIL-2
Medium +rEL-2 +IL-2 +mAba Medium +rIL-2 +IL-2 +mAba
CD3 50 45 80 20 30 50
TCRap 45 45 80 15 30 55
CD4 30 25 60 15 15 40
CD 8 25 25 20 10b 20b
CD56 10 10 0 20 50 20
CD25 3 2 75 1 35 50
a mAb: anti-CD28 (1 M-g/ml) plus immobilized anti-CD3 (0.5 ^Lg/well) 
b The percentage of CD8+ is strongly influenced by the presence of a 
significant number of CD8dim natural killer cells
100 ju,g/mi kanamycin. The PBL were cultured in IMDM with 5% pooled 
human serum, 100 U/ml penicillin and 100 |ig/ml kanamycin for 5 days.
Cell-mediated cytotoxicity assay. Samples containing 1 x 103 labelled 
target cells (11 |xCi 51Cr/106 cells, Amersham, Buckinghamshire, UK) 
were incubated in V-bottom microti ter plates with 3 x 104 effector cells 
in 150 jil IMDM with 0.25% bovine serum albumin. The plates were 
centrifuged for 5 min at 50 g and incubated at 37° C and 5% CO2 for 4 h. 
After the incubation period 100 \xl supernatant was collected from each 
well and counted in a gamma counter. All tests were carried out in 
triplicate. The spontaneous and the maximal release (cpm) were deter­
mined by incubation of targets in medium without effectors or in deter­
gent (Triton-XlOO) respectively. The percentage specific lysis was calcu­
lated by the formula [(experimental release -  spontaneous release)/(max­
imal release -  spontaneous release)] x  100.
Immuno-phenotyping o f PBL effector cells. Cell surface phenotyping of 
the isolated PBL was performed by fluorescence-activated cell sorter 
(FACScan), Becton-Dickinson) analysis using monoclonal antibodies 
against the surface antigens CD2 (CLB-T11.1/1, Central Laboratory of 
Blood Transfusion Service, CLB, Amsterdam, the Netherlands), CD3 
(SPV-T3b, Netherlands Cancer Institute), CD4 (Ortho Diagnostics, Til­
burg, the Netherlands), CD8 (Ortho Diagnostics, Tilburg, the Nether­
lands), CD25 (TB30, CLB), TCRap (BMA 031, Kurrle R, Behring 
Werke, Marburg, FRG), and CD56 (Leu 19, Becton-Dickinson, Etten- 
Leur, the Netherlands).
Immuno-phenotyping of the mononuclear infiltrate o f the renal cell car-  
cinoma and the interstitial nephritis. Immuno-phenotyping of the lym­
phocytes was performed on the cellular infiltrate of tie nephrectomy 
specimen of the original renal cell carcinoma and the biopsy demonstrat­
ing the tubulo-interstitial nephritis taken'2 weeks after discontinuation of 
the rIL-2. Immunohistochemical assays were performed on fresh frozen 
sections using an indirect immunoperoxidase technique. To inhibit endo­
genous peroxidase activity, slides were preincubated in a HiOa/acetone 
solution (3:10000) for 10 min at room temperature. The following anti­
bodies were used: anti-CD4 (Dako-T4, Glostrup, Denmark), anti-CD8 
(Dako, Gloslrup, Denmark), anti-CD 16 (Netherlands Cancer Institute), 
anti-CD25 (Becton Dickinson) and anti-CD56 (Becton Dickinson).
Results
Characterization o f the effector cells
The surface-marker profile of the PBL used as effector 
cells, sampled before and at the end of the 6 week rIL-2 
treatment, is presented in Table 1. After 6 weeks of rIL-2
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Fig. 1. In vitro cytotoxic activity ( ±  standard deviation) of the peripheral 
blood lymphocytes isolated before and at the end of continuous recombi­
nant interleukin-2 (rIL-2) treatment for 6 weeks against various autolo­
gous (a) and allogeneic (b) targets. The effector peripheral blood lym­
phocytes (PBL) were cultured for 5 days in medium alone, or stimulated 
with 600 IU/m rlL-2, with or without anti-CD28 (1 (ig/ml) plus immobi­
lized anti-CD3 (0.5 jxg/well) (mAb). The effector: target ratio was 30:1. 
PBL, autologous peripheral blood lymphocytes; ARCL, autologous renal 
cell line; BA, allogeneic renal cancer cell line; M14, NK-resistant mela­
noma cell line; K562, NK-sensitive erythroleukemia cell line
treatment a dramatic decrease in the percentage of CD3+ 
T cells (from 50% to 20%) was observed, without signifi­
cant changes in the CD4/CD8 ratio, and a small increase in 
the percentage of CD56+ natural killer cells.
After in vitro rIL-2 stimulation, the PBL taken after 
6 weeks of rIL-2 treatment had a high percentage of natural 
killer cells (50%) and an increased number of CD25+ cells.
In vitro stimulation of the pretreatment PBL with rIL-2 
and immobilized anti-CD3 plus anti-CD28 antibodies re­
sulted in preferential outgrowth of CD3+ T cells, the ma­
jority (60%) being CD4+ cells. After 6 weeks of rEL-2 
treatment the number of CD56+ natural killer cells (20%) 
was enhanced with a concomitant decrease in the percent­
age of CD3+ cells without changes in the CD4/CD8 ratio. 
The number of CD25+ cells was closely correlated with the 
number of CD3+ cells.
Immuno-pheno typing o f the mononuclear infiltrates of the 
renal cell carcinoma and the acute interstitial nephritis
In the tumour-associated mononuclear infiltrate and in that 
of the tubulo-interstitial nephritis there was an equal distri­
bution between the CD4+ (35/40%) and CD8+ (35/40%) 
CD3+ T lymphocytes and CD56+ (5/10%) cells.
Cytotoxic capacity o f the effector cells
The cytotoxic capacity of the PBL, isolated before and at 
the end of the 6 weeks of rIL~2 treatment, towards the 
various target cells is depicted in Fig. I a, b. It is demon­
strated in Fig, 1 a that after in vitro stimulation of the PBL 
with rIL-2 the cytotoxic capacity of the PBL, taken after 
6 weeks of rIL-2 treatment, has evidendy increased 
towards the autologous renal cell line (ARCL) isolated 
from the interstitial nephritis biopsy, but not towards autol­
ogous PBL. The cytotoxic activity of the PBL was not 
significantly influenced by the addition of anti-CD28 and 
immobilized anti-CD3 antibodies to rIL-2 in the medium.
The cytotoxic capacity of the isolated PBL towards 
various allogeneic targets is shown in Fig. 1 b. The PBL 
isolated at the end of rIL-2 treatment and cultured in me­
dium displayed evident killing of K562 (NK activity). 
After in vitro stimulation, the cytotoxic capacity of the 
PBL, isolated after 6 weeks of rIL-2 treatment, towards 
K562 and the allogeneic renal cancer cell line was en­
hanced in comparison with that of the PBL isolated before 
rIL-2 treatment. In contrast, there was no enhanced cyto­
toxicity against the allogeneic melanoma cell line M 14.
Discussion
This paper describes the immunological studies performed 
in the first biopsy-proven case of acute (tubulo)interstidal 
nephritis (AIN) after treatment with rIL-2 alone in a patient 
with advanced renal cell cancer [8]. In the present case, no 
complement or antibody deposition on the tubular base­
ment membrane (TBM) was observed, and there was no 
serologial evidence for complement activation or circulat­
ing anti-TBM antibodies. Therefore, we investigated 
whether the AIN was the result of a cell-mediated immune 
reaction induced by the rIL-2 treatment. We demonstrated 
that after 6 weeks of rIL-2 treatment the peripheral blood 
lymphocytes (PBL) of the patient, when stimulated in vi­
tro, displayed enhanced cytotoxic capacity towards an au­
tologous renal cell line (ARCL) cultured from the AIN 
biopsy specimen but not towards autologous PBL. In addi­
tion we observed enhanced killing of the allogeneic renal 
cancer cell line BA but not of the allogeneic melanoma cell 
line M14. These data may suggest that rIL-2 treatment in 
this patient with renal cell cancer led to the induction of 
cytotoxic lymphocytes with preferential lytic activity 
directed against renal cells, which may have led to im- 
mune-mediated renal injury. The question arises whether 
this injury is mediated by a non-specific or a specific 
cellular immune reaction. Essentially, non-specific and 
non-MHC(major histocompatibility complex)-restricted 
killing of targets is mediated by natural killer (NK) cells, 
whereas T lymphocytes exert antigen-specific MHC-re- 
stricted cytotoxicity. Recent data suggest that NK cells 
may also exhibit allo-antigen-specific cytotoxicity [5] and 
that T lymphocytes can, upon IL-2 activation, display non­
specific and MHC-unrestricted cytolysis [6]. From the ex-
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periments we performed, using bulk PBL that contain both 
T lymphocytes and NK cells, the nature of the cytotoxic 
reaction could not be determined with certainty.
During treatment with rIL-2, cells are generated that 
display non-specific and non-MHC-restricted cytotoxicity 
for a wide range of targets [12]. Although it was initially 
thought that these lymphokine-activated killer (LAK) cells 
should spare normal tissue, LAK cells may be cytotoxic for 
autologous lymphocytes and normal human cell lines in- 
eluding renal tubular cells [19, 24]. It may questioned 
whether the observed cytolytic activity of the in vitro 
stimulated PBL, isolated at the end of rIL-2 treatment, 
towards ARCL but not towards autologous PBL, may have 
played an actual role in the pathogenesis of AIN and does 
not merely represent a difference in LAK sensitivity be­
tween two different autologous targets.
Alternatively, in view of the recently demonstrated 
presence of tumour-specific cytotoxic T cells in renal-cell- 
cancer-infiltrating lymphocytes [15] and the possible role 
of tubular-antigen-specific cytotoxic T cells in the patho­
genesis of experimental AIN [13], a specific T-cell-medi- 
ated reaction must be considered. Since renal cell carcino­
ma originates from the epithelial cells of the proximal 
tubulus and may express a number of cell-surface-as- 
sociated antigens, that are shared by the various parts of the 
normal nephron [9, 22], a T cell response evoked against 
an antigen present on the tumour cells could display cross­
reactivity with antigens present on the normal tubulo-inter- 
stitium. This “autoimmune” response could have been en­
hanced by the rIL-2 treatment leading to the cell-mediated 
AIN in the other kidney [17].
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